Pharmaceuticals, Biotechnology and Life Sciences
GeNeuro and Servier on Monday said that GNbAC1, for the treatment of certain multiple sclerosis was well tolerated, without statistical…
Sanofi has acquired USA based Protein Sciences, a vaccines biotechnology company located in Meriden, Connecticut. The Federal Trade Commission’s approval…
CF PharmTech has raised $65M in a Series D financing with a future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited, led the financing along with other prestigious healthcare investment groups in China.
Lumosa Herapeutics said Monday that the FDA has confirmed its submission of the NDA of LT1001 Naldebain in the US. Naldebain IM injection has received market authorization and launched in Taiwan as the world’s first 7-day long-acting analgesic injection for moderate to severe post-operative pain.
Novartis has revealed primary data from CANTOS, a Phase III study evaluating quarterly injections of ACZ885 (canakinumab) in people with a prior heart attack and inflammatory atherosclerosis as measured by high-sensitivity C-reactive protein (hsCRP) levels of >=2mg/L, a known marker of inflammation.
The U.S. Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV disease.
Attorney Jonathan Emord and his co-counsel Kendrick Moxon have added to their Citizen Petition of August 2016, against the FDA’s Proposed Order to reclassify and make more readily available the Electroconvulsive Therapy (ECT) Device used to give “shock-treatment.” The reclassification would make it easier for doctors to give the treatment, which – pointed out by Emord & Associates, P.C – is well-known as the punishment given actor Jack Nicholson in the movie One Flew Over the Cuckoo’s Nest.
Prommune has completed completion of its third proof of concept study in pigs for its lead products HeptaVac, a self-adjuvating peptide vaccine cocktail and HISP-P, an immunoactivator and molecular adjuvant both for use in pigs with Swine Influenza A Virus infections.
Otsuka Pharmaceutical and Mylan N.V. have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries.
Karo Pharma will launch voluntary cash offer to acquire the entire issued share capital of Weifa for € 3.78 per share in cash.